Pharmaceutical

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel…

12 months ago

Compass Therapeutics Provides Corporate Update

We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x…

12 months ago

Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China

Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet patient need…

12 months ago

TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Presentation scheduled for Tuesday, January 9, 2024, at 4:30 PM PTNEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics,…

12 months ago

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity – Associated Inflammation

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…

12 months ago

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

RAPIDe-3, a global Phase 3 clinical study of deucrictibant for the on-demand treatment of HAE, to initiate within 1H24Results of…

12 months ago

Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer

ORION CORPORATION PRESS RELEASE05 JANUARY 2023 at 13:45 EET                      Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684…

12 months ago

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new…

12 months ago

Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer

Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today…

12 months ago